A Study of Petosemtamab With Pembrolizumab in People With Non-Small Cell Lung Cancer

Full Title

A Phase 2 Study to Investigate the Safety and Efficacy of Petosemtamab in Combination with Docetaxel as Second-Line Treatment in Adults with Metastatic Non-Small Cell Lung Cancer or in Combination with Pembrolizumab as First-Line Treatment

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Paul Paik’s office at 646-608-3759.

Protocol
26-128
Phase
Phase II (phase 2)
Disease Status
Relapsed or Refractory
Investigator
Paul K. Paik
Co-Investigators
Mark Awad
Diseases
Lung Cancer › Lung Cancer, Non-Small Cell
Locations
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Commack Nonna’s Garden Foundation Center
Memorial Sloan Kettering Basking Ridge
Memorial Sloan Kettering Westchester
Memorial Sloan Kettering Monmouth
Memorial Sloan Kettering Bergen
Memorial Sloan Kettering Nassau
ClinicalTrials.gov ID
NCT07353957
ClinicalTrials.gov
Visit ClinicalTrials.gov for full clinical trial description